35 related articles for article (PubMed ID: 14996401)
1. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
Martinez-Lopez A; Cuenca-Barrales C; Montero-Vilchez T; Molina-Leyva A; Arias-Santiago S
J Am Acad Dermatol; 2020 Dec; 83(6):1738-1748. PubMed ID: 32777318
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
3. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
4. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
[TBL] [Abstract][Full Text] [Related]
5. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
7. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Bongiovanni M; Chiesa E; Monforte Ad; Bini T
Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
[No Abstract] [Full Text] [Related]
8. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
Moltó J; Clotet B
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
Tan D; Walmsley S
Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Barragan P; Podzamczer D
Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
[TBL] [Abstract][Full Text] [Related]
11. [Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].
Jiménez FJ; Pinilla J; Repiso M; Labarga P
Enferm Infecc Microbiol Clin; 2002 Oct; 20(8):418. PubMed ID: 12372245
[No Abstract] [Full Text] [Related]
12. [Lopinavir/ritonavir monotherapy. Possible indications].
López Aldeguer J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():21-3. PubMed ID: 19572440
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
